Long noncoding RNA LGALS8-AS1 promotes angiogenesis and brain metastases in non-small cell lung cancer

Jian Zhong; Bo Wang

doi:10.18388/abp.2020_6501

Long noncoding RNA LGALS8-AS1 promotes angiogenesis and brain metastases in non-small cell lung cancer

Jian Zhong 1Department of Thoracic Surgery, Affiliated Brain Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, 210000, China; 2Department of Thoracic surgery, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
Bo Wang 1Department of Thoracic Surgery, Affiliated Brain Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, 210000, China; 2Department of Thoracic surgery, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China https://orcid.org/0000-0002-0093-1935

DOI: https://doi.org/10.18388/abp.2020_6501

Abstract

Brain metastases (BM) are associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Considering that, LGAS8-AS1-mediated progression of BM was probed in NSCLC. The clinical characteristics of 60 NSCLC patients (30 without BM and 30 with BM) were analyzed. NSCLC patients with BM had higher levels of LGALS8-AS1 than NSCLC patients without BM. Depleting LGALS8-AS1 prevented NSCLC cell proliferation, migration, invasion, and angiogenesis in vitro, and NSCLC tumorigenesis and BM in vivo. LGALS8-AS1 targeted miR-885-3p to mediate Fascin actin-bundling protein 1 (FSCN1) expression. Restoring miR-885-3p inhibited NSCLC growth, angiogenesis, and BM, and FSCN1 induction rescued the performance of LGALS8-AS1 depletion on NSCLC cells. Our results provide new insights into LGALS8-AS1-mediated NSCLC metastasis and suggest that LGALS8-AS1 may be a useful biomarker for identifying NSCLC with metastatic potential.

pdf
html

Published

2023-09-16

Issue

Vol. 70 No. 3 (2023)

Section

Articles

This work is licensed under a Creative Commons Attribution 4.0 International License.

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.